Phase II Randomized Study of Plitidepsin (Aplidin), Alone or in Association with L-carnitine, in Patients with Unresectable Advanced Renal Cell Carcinoma
Open Access
- 5 March 2009
- journal article
- research article
- Published by MDPI AG in Marine Drugs
- Vol. 7 (1) , 57-70
Abstract
This randomized phase II study evaluated two schedules of the marine compound Plitidepsin with or without co-administration of L-carnitine in patients with renal cell carcinoma. Patients had adequate performance status and organ function.The primary endpoint was the rate of disease control (no progression) at 12 weeks (RECIST).Other endpoints included the response rate and time dependent efficacy measures.The trial also assessed the efficacy of L-carnitine to prevent Plitidepsin-related toxicity. The two regimes given as 24 hour infusion every two weeks showed hints of antitumoral activity. Disease control at 12 weeks was 15.8% in Arm A (5mg/m2, no L-carnitine) and 11,1% in Arm B (7mg/m2 with L-carnitine). Two partial responses were observed in Arm A (19 patients), none in Arm B (20 patients). Both schedules had the same progression-free interval (2.1 months).The median overall survival was 7.0 and 7.6 months.The safety profile was similar in both arms of the trial and adverse events were mainly mild to moderate (NCI CTC version 2.0). Increasing the dose to 7mg/m2 did not increase the treatment efficacy but the incidence of transaminase and CPK elevations and serious AEs. Coadministration of L-carnitine did not prevent muscular toxicity or CPK-elevation associated with Plitidepsin.Keywords
This publication has 23 references indexed in Scilit:
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell CarcinomaThe Oncologist, 2007
- Fishing for New DrugsJournal of Clinical Oncology, 2005
- VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemiaAnnals of Oncology, 2005
- Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal CarcinomaClinical Cancer Research, 2004
- C-Met Proto-Oncogene Expression in Benign and Malignant Human Renal TissuesJournal of Urology, 1997
- C-Met Proto-Oncogene Expression in Benign and Malignant Human Renal TissuesJournal of Urology, 1997
- Growth and Chemotherapeutic Response of Cells in a Hollow-Fiber In Vitro Solid Tumor ModelJNCI: Journal of the National Cancer Institute, 1994
- Renal Carcinoma in Patients Undergoing Nephrectomy: Analysis of Survival and Prognostic FactorsBritish Journal of Urology, 1992
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987